Rare long-term survivors of pancreatic adenocarcinoma without curative resection

World Journal of Gastroenterology

Volumn 21, Issue 48, 2015, Pages 13574-13581

  Oh, Stephen Y ^a   Edwards, Alicia ^a   Mandelson, Margaret T ^a   Lin, Bruce ^a   Dorer, Russell ^a   Helton, W Scott ^a   Kozarek, Richard A ^a   Picozzi, Vincent J ^a  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

5 year survival; Chemotherapy; Cholangitis; Long term survival; Malnutrition; Non resected pancreatic cancer; Second malignancy

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; DOCETAXEL; FLUOROURACIL; GEMCITABINE;

ADULT; AGED; ARTICLE; BILIARY TRACT DRAINAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVOR; CHOLANGITIS; DISEASE COURSE; DUODENUM STENT; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HOSPITALIZATION; HUMAN; HUMAN TISSUE; INTESTINE PERFORATION; KIDNEY CARCINOMA; MALE; MALNUTRITION; MIDDLE AGED; PANCREAS ADENOCARCINOMA; PANCREAS BIOPSY; SECOND CANCER; SMALL INTESTINE PERFORATION; STOMACH OBSTRUCTION; VERY ELDERLY; ADENOCARCINOMA; CASE REPORT; COMORBIDITY; PANCREATIC NEOPLASMS; PATHOLOGY; RISK FACTOR; SURVIVOR; TIME FACTOR; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; COMORBIDITY; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RISK FACTORS; SURVIVORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84953273708     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i48.13574     Document Type: Article

References (51)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300 [PMID: 20610543 DOI: 10.3322/caac.20073]
2. Baxter NN, Whitson BA, Tuttle TM. Trends in the treatment and outcome of pancreatic cancer in the United States. Ann Surg Oncol 2007; 14: 1320-1326 [PMID: 17225980]
3. Zell JA, Rhee JM, Ziogas A, Lipkin SM, Anton-Culver H. Race, socioeconomic status, treatment, and survival time among pancreatic cancer cases in California. Cancer Epidemiol Biomarkers Prev 2007; 16: 546-552 [PMID: 17372250]
4. Lau MK, Davila JA, Shaib YH. Incidence and survival of pancreatic head and body and tail cancers: a population-based study in the United States. Pancreas 2010; 39: 458-462 [PMID: 19924019 DOI: 10.1097/MPA.0b013e3181bd6489]
5. Eloubeidi MA, Desmond RA, Wilcox CM, Wilson RJ, Manchikalapati P, Fouad MM, Eltoum I, Vickers SM. Prognostic factors for survival in pancreatic cancer: a population-based study. Am J Surg 2006; 192: 322-329 [PMID: 16920426]
6. Sun H, Ma H, Hong G, Sun H, Wang J. Survival improvement in patients with pancreatic cancer by decade: a period analysis of the SEER database, 1981-2010. Sci Rep 2014; 4: 6747 [PMID: 25339498 DOI: 10.1038/srep06747]
7. Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg 1990; 211: 447-458 [PMID: 2322039]
8. Cameron JL, Crist DW, Sitzmann JV, Hruban RH, Boitnott JK, Seidler AJ, Coleman J. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 1991; 161: 120-124; discussion 124-125 [PMID: 1987845]
9. Ahmad NA, Lewis JD, Ginsberg GG, Haller DG, Morris JB, Williams NN, Rosato EF, Kochman ML. Long term survival after pancreatic resection for pancreatic adenocarcinoma. Am J Gastroenterol 2001; 96: 2609-2615 [PMID: 11569683]
10. Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, Trede M. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 2003; 27: 324-329 [PMID: 12607060]
11. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Büchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004; 91: 586-594 [PMID: 15122610]
12. Cleary SP, Gryfe R, Guindi M, Greig P, Smith L, Mackenzie R, Strasberg S, Hanna S, Taylor B, Langer B, Gallinger S. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg 2004; 198: 722-731 [PMID: 15110805]
13. Howard TJ, Krug JE, Yu J, Zyromski NJ, Schmidt CM, Jacobson LE, Madura JA, Wiebke EA, Lillemoe KD. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer. J Gastrointest Surg 2006; 10: 1338-1345; discussion 1345-1346 [PMID: 17175452]
14. Riall TS, Cameron JL, Lillemoe KD, Winter JM, Campbell KA, Hruban RH, Chang D, Yeo CJ. Resected periampullary adenocarcinoma: 5-year survivors and their 6-to 10-year follow-up. Surgery 2006; 140: 764-772 [PMID: 17084719]
15. Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, Hodgin MB, Sauter PK, Hruban RH, Riall TS, Schulick RD, Choti MA, Lillemoe KD, Yeo CJ. 1423 pancreaticoduodenectomies for pancreatic cancer: A singleinstitution experience. J Gastrointest Surg 2006; 10: 1199-210; discussion 1210-1211 [PMID: 17114007]
16. Han SS, Jang JY, Kim SW, Kim WH, Lee KU, Park YH. Analysis of long-term survivors after surgical resection for pancreatic cancer. Pancreas 2006; 32: 271-275 [PMID: 16628082]
17. Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, Gullerud RE, Donohue JH, Nagorney DM, Farnell MB. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg 2008; 247: 456-462 [PMID: 18376190 DOI: 10.1097/SLA.0b013e3181613142]
18. Ferrone CR, Brennan MF, Gonen M, Coit DG, Fong Y, Chung S, Tang L, Klimstra D, Allen PJ. Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg 2008; 12: 701-706 [PMID: 18027062]
19. Nathan H, Wolfgang CL, Edil BH, Choti MA, Herman JM, Schulick RD, Cameron JL, Pawlik TM. Peri-operative mortality and long-term survival after total pancreatectomy for pancreatic adenocarcinoma: a population-based perspective. J Surg Oncol 2009; 99: 87-92 [PMID: 19021191 DOI: 10.1002/jso.21189]
20. Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, Varadhachary G, Abbruzzese JL, Crane CH, Krishnan S, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 2009; 16: 836-847 [PMID: 19194760 DOI: 10.1245/s10434-008-0295-2]
21. Shimada K, Sakamoto Y, Nara S, Esaki M, Kosuge T, Hiraoka N. Analysis of 5-year survivors after a macroscopic curative pancreatectomy for invasive ductal adenocarcinoma. World J Surg 2010; 34: 1908-1915 [PMID: 20376443 DOI: 10.1007/s00268-010-0570-9]
22. Ferrone CR, Pieretti-Vanmarcke R, Bloom JP, Zheng H, Szymonifka J, Wargo JA, Thayer SP, Lauwers GY, Deshpande V, Mino-Kenudson M, Fernández-del Castillo C, Lillemoe KD, Warshaw AL. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery 2012; 152: S43-S49 [PMID: 22763261 DOI: 10.1016/j.surg.2012.05.020]
23. Dusch N, Weiss C, Ströbel P, Kienle P, Post S, Niedergethmann M. Factors predicting long-term survival following pancreatic resection for ductal adenocarcinoma of the pancreas: 40 years of experience. J Gastrointest Surg 2014; 18: 674-681 [PMID: 24241965 DOI: 10.1007/s11605-013-2408-x]
24. Chong I, Cunningham D. Pancreatic Cancer. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson J, Loscalzo J. editors. Harrison's Principles of Internal Medicine, 18e. New York: McGraw-Hill, 2012: 786-789
25. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combinedmodality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 1988; 80: 751-755 [PMID: 2898536]
26. Picozzi VJ, Abrams RA, Decker PA, Traverso W, O'Reilly EM, Greeno E, Martin RC, Wilfong LS, Rothenberg ML, Posner MC, Pisters PW; American College of Surgeons Oncology Group. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Ann Oncol 2011; 22: 348-354 [PMID: 20670978 DOI: 10.1093/annonc/mdq384]
27. Spinelli GP, Zullo A, Romiti A, Di Seri M, Tomao F, Miele E, Spalletta B, Eramo A, Hassan C, Tomao S. Long-term survival in metastatic pancreatic cancer. A case report and review of the literature. JOP 2006; 7: 486-491 [PMID: 16998247]
28. Okamoto Y, Maeba T, Kakinoki K, Okano K, Izuishi K, Wakabayashi H, Usuki H, Suzuki Y. A patient with unresectable advanced pancreatic cancer achieving long-term survival with gemcitabine chemotherapy. World J Gastroenterol 2008; 14: 6876-6880 [PMID: 19058319 DOI: 10.3748/wjg.14.6876]
29. Matsukawa H, Shiozaki S, Takakura N, Aoki H, Fujiwara Y, Ohno S, Ojima Y, Harano M, Nishizaki M, Choda Y, Ninomiya M. [A 6-year survival case of locally advanced unresectable pancreatic tail cancer treated with chemo-radiation therapy]. Gan To Kagaku Ryoho 2010; 37: 2355-2357 [PMID: 21224571]
30. Chohno T, Aoki T, Hyuga S, Watanabe R, Matsumoto T, Takemoto H, Takachi K, Nishioka K, Uemura Y, Kobayashi K. [Long-term survival of a patient with locally advanced unresectable pancreatic cancer treated with gemcitabine after chemoradiation therapy]. Gan To Kagaku Ryoho 2013; 40: 1881-1883 [PMID: 24393953]
31. Krzyzanowska MK, Weeks JC, Earle CC. Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness. J Clin Oncol 2003; 21: 3409-3414 [PMID: 12972517]
32. Shaib YH, Davila JA, El-Serag HB. The epidemiology of pancreatic cancer in the United States: changes below the surface. Aliment Pharmacol Ther 2006; 24: 87-94 [PMID: 16803606]
33. Rohan VS, Hsu JT, Liu KH, Yeh CN, Yeh TS, Jan YY, Hwang TL. Long-term results and prognostic factors in resected pancreatic body and tail adenocarcinomas. J Gastrointest Cancer 2013; 44: 89-93 [PMID: 23076797 DOI: 10.1007/s12029-012-9448-4]
34. Michaud DS, Giovannucci E, Willett WC, Colditz GA, Stampfer MJ, Fuchs CS. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA 2001; 286: 921-929 [PMID: 11509056]
35. Arslan AA, Helzlsouer KJ, Kooperberg C, Shu XO, Steplowski E, Bueno-de-Mesquita HB, Fuchs CS, Gross MD, Jacobs EJ, Lacroix AZ, Petersen GM, Stolzenberg-Solomon RZ, Zheng W, Albanes D, Amundadottir L, Bamlet WR, Barricarte A, Bingham SA, Boeing H, Boutron-Ruault MC, Buring JE, Chanock SJ, Clipp S, Gaziano JM, Giovannucci EL, Hankinson SE, Hartge P, Hoover RN, Hunter DJ, Hutchinson A, Jacobs KB, Kraft P, Lynch SM, Manjer J, Manson JE, McTiernan A, McWilliams RR, Mendelsohn JB, Michaud DS, Palli D, Rohan TE, Slimani N, Thomas G, Tjønneland A, Tobias GS, Trichopoulos D, Virtamo J, Wolpin BM, Yu K, Zeleniuch-Jacquotte A, Patel AV. Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch Intern Med 2010; 170: 791-802 [PMID: 20458087 DOI: 10.1001/archinternmed.2010.63]
36. Larsson SC, Orsini N, Wolk A. Body mass index and pancreatic cancer risk: A meta-analysis of prospective studies. Int J Cancer 2007; 120: 1993-1998 [PMID: 17266034]
37. Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, Murphy R, Ghosh S, Sawyer MB, Baracos VE. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013; 31: 1539-1547 [PMID: 23530101 DOI: 10.1200/JCO.2012.45.2722]
38. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, Baracos VE. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008; 9: 629-635 [PMID: 18539529 DOI: 10.1016/S1470-2045(08)70153-0]
39. Huguet F, André T, Hammel P, Artru P, Balosso J, Selle F, Deniaud-Alexandre E, Ruszniewski P, Touboul E, Labianca R, de Gramont A, Louvet C. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007; 25: 326-331 [PMID: 17235048]
40. Gutt R, Liauw SL, Weichselbaum RR. The role of radiotherapy in locally advanced pancreatic carcinoma. Nat Rev Gastroenterol Hepatol 2010; 7: 437-447 [PMID: 20628346 DOI: 10.1038/nrgastro.2010.98]
41. Loehrer PJ, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, Flynn P, Ramanathan RK, Crane CH, Alberts SR, Benson AB. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 2011; 29: 4105-4112 [PMID: 21969502 DOI: 10.1200/JCO.2011.34.8904]
42. Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2007; 68: 809-816 [PMID: 17363191]
43. Krishnan S, Rana V, Janjan NA, Varadhachary GR, Abbruzzese JL, Das P, Delclos ME, Gould MS, Evans DB, Wolff RA, Crane CH. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 2007; 110: 47-55 [PMID: 17538975]
44. Rasheed ZA, Yang J, Wang Q, Kowalski J, Freed I, Murter C, Hong SM, Koorstra JB, Rajeshkumar NV, He X, Goggins M, Iacobuzio-Donahue C, Berman DM, Laheru D, Jimeno A, Hidalgo M, Maitra A, Matsui W. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst 2010; 102: 340-351 [PMID: 20164446 DOI: 10.1093/jnci/djp535]
45. Javle MM, Gibbs JF, Iwata KK, Pak Y, Rutledge P, Yu J, Black JD, Tan D, Khoury T. Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer. Ann Surg Oncol 2007; 14: 3527-3533 [PMID: 17879119]
46. Krantz SB, Shields MA, Dangi-Garimella S, Munshi HG, Bentrem DJ. Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. J Surg Res 2012; 173: 105-112 [PMID: 22099597 DOI: 10.1016/j.jss.2011.09.020]
47. Fogelman DR, Wolff RA, Kopetz S, Javle M, Bradley C, Mok I, Cabanillas F, Abbruzzese JL. Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Res 2011; 31: 1417-1420 [PMID: 21508395]
48. Vyas O, Leung K, Ledbetter L, Kaley K, Rodriguez T, Garcon MC, Saif MW. Clinical outcomes in pancreatic adenocarcinoma associated with BRCA-2 mutation. Anticancer Drugs 2015; 26: 224-226 [PMID: 25304989 DOI: 10.1097/CAD.0000000000000178]
49. Amedei A, Niccolai E, Benagiano M, Della Bella C, Cianchi F, Bechi P, Taddei A, Bencini L, Farsi M, Cappello P, Prisco D, Novelli F, D'Elios MM. Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions. Cancer Immunol Immunother 2013; 62: 1249-1260 [PMID: 23640603]
50. Amedei A, Niccolai E, Prisco D. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy. Hum Vaccin Immunother 2014; 10: 3354-3368 [PMID: 25483688]
51. Szkandera J, Stotz M, Eisner F, Absenger G, Stojakovic T, Samonigg H, Kornprat P, Schaberl-Moser R, Alzoughbi W, Ress AL, Seggewies FS, Gerger A, Hoefler G, Pichler M. External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients. PLoS One 2013; 8: e78225 [PMID: 24223776 DOI: 10.1371/journal.pone.0078225]